Grufity logo
Grufity logo
NNVC

NNVC - NanoViricides Inc Stock Price, Fair Value and News

$1.73-0.04 (-2.26%)
Delayed as of 15 Jul 2026, 12:11 pm ET

Price Targets

NNVC Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

NNVC Price Action

Last 7 days

10%

Last 30 days

35.3%

Last 90 days

58.7%

Trailing 12 Months

17.9%

NNVC RSI Chart

NNVC Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

NNVC Valuation

Market Cap

38.3M

Price/Earnings (Trailing)

-4.74

EV/EBITDA

-5.54

Price/Free Cashflow

-5.2

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

NNVC Fundamentals

NNVC Earnings

Earnings (TTM)

-8.1M

Earnings Growth (Yr)

10.26%

Earnings Growth (Qtr)

10.42%

NNVC Profitability

Return on Equity

-88.39%

Return on Assets

-79.18%

Free Cashflow Yield

-19.24%

NNVC Investor Care

Shares Dilution (1Y)

35.07%

Diluted EPS (TTM)

-0.42

Revenue & Growth

How NanoViricides Inc generates revenue and covers its expenses, based on the latest reported earnings.

About NanoViricides Inc

NNVC
NanoViricides, Inc., a nano-biopharmaceutical research and development company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company develops Monkeypox Treatment for Monkeypox virus; Adenovirus 71 Treatment for severe pediatric hepatitis caused by Adenovirus 71 or related viruses; and HerpeCide Program Expansion Drug project that develops broad-spectrum nanoviricide drugs against different herpes viruses for different indications. The company also develops FluCide Broad-Spectrum Anti-Influenza nanoviricide, which is injectable for hospitalized patients and oral for outpatients; Nanoviricide eye drops for viral diseases of the external eye; DengueCide for treatment of various types of Dengue viruses; and HIVCide, an escape-resistant anti-HIV nanoviricide. In addition, it develops other nanoviricides drug projects for treatment of different viruses and indications; and HerpeCide program expansion drug projects for different herpes viruses for different indications. The company was founded in 2005 and is based in Shelton, Connecticut.
 CEO
 WEBSITEnanoviricides.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES17

NanoViricides Inc Frequently Asked Questions

NNVC is the stock ticker symbol of NanoViricides Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Tue Jul 14 2026, market cap of NanoViricides Inc is 38.32 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

In the past 10 years, NanoViricides Inc has provided -0.258 (multiply by 100 for percentage) rate of return.